MADRIGAL PHARMACEUTICALS INC (MDGL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MDGL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | Senior Scientific and Medical Advisor and Former President of Research & Development and Chief Medical Officer and Class II Director | 74 | ["Chief Medical Officer of Madrigal from July 2016 to April 2025","President, Research & Development from June 2019 to April 2025","Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. from 2008 to 2011","Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche AG from 2004 to 2008","Various capacities at Bristol-Myers Squibb Company and DuPont from 2000 through 2003","Tenured Professor of Genetics and Medicine at the University of Pennsylvania from 1987 to 2002","Adjunct professor","Assistant Professor at the Joslin Diabetes Center of Harvard Medical School","Author of more than 120 research articles"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Served as Chief Medical Officer of Madrigal from July 2016 to April 2025 and as President, Research & Development from June 2019 to April 2025 when she transitioned to a Senior Scientific and Medical Advisor role. Served as Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. from 2008 to 2011 and Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche AG from 2004 to 2008 where she oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases, including the conduct of a series of Phase 1 and 2 proof of concept clinical trials. Served in various capacities at Bristol-Myers Squibb Company and DuPont from 2000 through 2003, including as Executive Director of central nervous system and metabolic diseases research at each company. Has authored more than 120 research articles. Tenured Professor of Genetics and Medicine at the University of Pennsylvania from 1987 to 2002, and remains an adjunct professor. Served as Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College. Other Company Board Service Dr. Taub has served on the board of directors of BriaCell Therapeutics Corp., Inc. since March 2019. Qualifications We believe that Dr. Taub is qualified to serve on our Board due to her experience as our Chief Medical Officer and President, Research and Development of Madrigal, and due to her extensive experience as a pharmaceutical executive leading major development programs in MASH.